almotriptan / Generic mfg. - LARVOL DELTA

Ischemic Colitis Reporting Across the Triptan Class: A Cross-Database Analysis With FDA Label Review (ACG 2026) - " We queried the FDA Adverse Event Reporting System (FAERS) and WHO VigiBase on 5/1/2026 for IC reports associated with sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, and frovatriptan... Sumatriptan had the highest absolute IC case volume (FAERS: 87 cases; VigiBase: 114 cases) consistent with its dominant overall reporting volume. Rizatriptan was the only agent with significantly elevated IC reporting proportions in both FAERS (1.76% vs 0.79%, p=0.0007) and VigiBase (0.55% vs 0.31%, p=0.009). Frovatriptan was elevated in FAERS only (4.48% vs 0.85%, p=0.020)."

Review • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Migraine

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

The association of acute medication utilization and clinician specialty in the treatment of pediatric chronic migraine: A cross-institutional electronic health record analysis (AHS 2026) - "Rizatriptan, sumatriptan, zolmitriptan, and almotriptan are approved for use in children, while gepants are not yet approved in children but may sometimes be used off-label. Among pediatric patients with chronic migraine, care through neurology was associated with significantly higher acute migraine medication utilization. Pediatric-only care was associated with lower rates of use, suggesting potential gaps in access or lower familiarity and comfort with migraine-specific treatments, leading to potential delays in optimal care. These findings highlight possible disparities in access to neurologists or other system-driven treatment gaps, rather than differences in clinical need for migraine-specific therapies."

Clinical • CNS Disorders • Migraine • Pain

Efficacy and safety of almotriptan for treatment of menstrual migraine: A systematic review (EHF-EHC 2025) - "In a large trial (n=255), almotriptan 12.5 mg and zolmitriptan 2.5 mg were compared and both demonstrated comparable efficacy. Almotriptan is effective and well tolerated for the acute treatment of menstrual migraine, showing superiority over placebo and comparable efficacy to other triptans. Frovatriptan may reduce recurrence more effectively, but larger, dedicated trials are needed to confirm these findings."

Clinical • Review • CNS Disorders • Migraine • Pain

A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy. (PubMed, J Pain Res) - "The report proportion varied among triptans, with naratriptan (12.23%) and almotriptan (12.15%) showing the highest rates, while sumatriptan (4.74%) had the lowest...Disproportionality analysis revealed significant signals for almotriptan (ROR=3.34), naratriptan (ROR=2.96), and rizatriptan (ROR=2.41), with almotriptan exhibiting the strongest association...Time-to-onset analysis showed frovatriptan had the earliest median onset (3.5 days), while almotriptan had the longest (284 days)...Clinicians should carefully evaluate cardiovascular risk factors before prescribing triptans and consider alternative treatments for susceptible individuals. Additional prospective studies are required to validate these findings."

Adverse events • Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Ischemic stroke • Migraine • Myocardial Infarction • Pain

Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system. (PubMed, PLoS One) - "Positive tinnitus signals were observed for several CGRP inhibitors, except eptinezumab and atogepant, and for all triptans except sumatriptan...However, intra-class analysis identified naratriptan, almotriptan, and frovatriptan as having notable tinnitus signals among triptans, while CGRP inhibitors did not exhibit strong signals for any specific drug. Using real-world data from FAERS and pharmacovigilance methods, this study identified tinnitus signals related to migraine treatments, particularly among certain triptans. These findings provide preliminary evidence for further investigation into the relationship between migraine medications and tinnitus."

Adverse events • Journal • CNS Disorders • Migraine • Otorhinolaryngology • Pain

Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis. (PubMed, J Pain Res) - "We conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database from 2004-2024, focusing on adverse events associated with sumatriptan, rizatriptan, zolmitriptan, and almotriptan in patients aged 6-18 years. Age-stratified analysis revealed distinct profiles: younger children (6-11 years) showed higher risks for gastric emptying impairment (ROR=331.24) and throat tightness (ROR=77.14), while adolescents (12-18 years) experienced more diverse adverse events, notably pharyngeal swelling (ROR=133.81) and chest discomfort (ROR=19.05). Real-world triptan safety profiles reveal age-specific risks in pediatric populations, emphasizing the need for tailored monitoring strategies and age-appropriate safety protocols."

Adverse events • Journal • CNS Disorders • Migraine • Pain • Pediatrics • Respiratory Diseases

ATOM: Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (clinicaltrials.gov) - P4 | N=8 | Terminated | Sponsor: Messoud Ashina, MD | N=645 ➔ 8 | Recruiting ➔ Terminated; Issues with recruitment

Enrollment change • Trial termination • CNS Disorders • Migraine • Pain

The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis. (PubMed, Front Neurol) - "In our interrupted time-series analysis, the introduction of the gepants and lasmiditan was linked to decreases in triptan utilization, except for eletriptan which remained stable, and rizatriptan which rose at a slower rate...Our study suggests increased headache provider availability is associated with more prescriptions for naratriptan, eletriptan, and almotriptan. Additionally, the introduction of the gepants and lasmiditan broadly decreased the utilization of triptans. Critically, there was a strong association between a pharmaceutical company's, Pfizer, payments to physicians and utilization of their medication, rimegepant."

Journal • CNS Disorders • Migraine • Pain

Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects. (PubMed, CNS Neurol Disord Drug Targets) - "At the moment, naratriptan, eletriptan, zolmitriptan, rizatriptan, almotriptan, and frovatriptan are the seven types of triptans available on the market. Among these are the FDA-approved triptans, Zolmitriptan and Sumatriptan, which are selective serotonin (5-hydroxytryptamine) agonists...The only known antimigraine drugs that were widely utilized before the triptan period were ergotamine and dihydroergotamine...Researchers have looked into fresh ideas for solving this issue and innovations to overcome its pharmacokinetic difficulties. This article emphasizes the role of zolmitriptan in the treatment of migraines, highlighting its pharmacological properties, production, metabolism, and structural features."

Journal • CNS Disorders • Migraine • Pain

Eight-teen years of triptan use in Korea: A nationwide population-based study (AHS 2024) - "The triptans available in Korea, listed in order of their release, are sumatriptan, naratriptan, zolmitriptan, almotriptan, and frovatriptan. Despite the exponential growth in the volume of triptan prescriptions, the proportion of migraine patients receiving triptans remains low, and there is significant variability in prescribing practices across medical specialties. Efforts to reduce the gap in treatment approaches among doctors through more education are needed."

Clinical • CNS Disorders • Migraine • Pain • Psychiatry

Rizatriptan as an Over-the-Counter Triptan in the Treatment of Migraine Attacks. (PubMed, Pain Ther) - "The results show that rizatriptan at a dose of 5 mg is more effective than the triptans naratriptan 2.5 mg, almotriptan 12.5 mg and sumatriptan 50 mg, which were previously available for self-medication in Germany. From a clinical care perspective, it is desirable for affected patients to have other options available for self-medication. Non-responders to other substances also have a further treatment option with rizatriptan 5 mg, with the same or even better risk-benefit profile, to treat migraine attacks safely, effectively and in a tolerable manner as part of self-medication."

Journal • Review • CNS Disorders • Migraine • Pain

The putative proton-coupled organic cation antiporter is involved in uptake of triptans into human brain capillary endothelial cells. (PubMed, Fluids Barriers CNS) - "We have demonstrated that the triptan family of compounds possesses affinity for the H+/OC antiporter proposing that the putative H+/OC antiporter plays a role in the BBB transport of triptans, particularly eletriptan. Our in vivo studies indicate that eletriptan is subjected to simultaneous brain uptake and efflux, possibly facilitated by the putative H+/OC antiporter and P-gp, respectively. Our findings offer novel insights into the potential central site of action involved in migraine treatment with triptans and highlight the significance of potential transporter related drug-drug interactions."

Journal • CNS Disorders • Migraine • Pain • ABCB1

The 5-HT and 5-HT agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans. (PubMed, Handb Clin Neurol) - "There is extensive evidence that the seven triptans available today, sumatriptan, zolmitriptan, rizatriptan, eletriptan, naratriptan, almotriptan, and frovatriptan, are effective in the acute treatment of migraine. For optimal benefit, therapy needs to be individualized for a given patient both regarding the triptan chosen and the formulation. This chapter discusses the ergot alkaloids and the triptans, including mechanism of action, evidence for efficacy, clinical use, and adverse effects."

Journal • CNS Disorders • Migraine • Pain

Unravelling the role of the putative proton-coupled organic cation antiporter in triptan transport across the blood-brain barrier (Neuroscience 2023) - "We applied human brain capillary endothelial cells (hCMEC/D3) to investigate uptake characteristics of prototypical H+/OC antiporter substrates and triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan). J Headache Pain. 2010; 11(1):5-12."

CNS Disorders • Migraine • Pain • ABCB1

QuEChERS-assisted ion pair chromatography/fluorescence detection method for determination of antimigraine combination therapy in rabbit plasma samples: Application to a pharmacokinetic study. (PubMed, J Pharm Biomed Anal) - "The presented study was conducted to investigate the pharmacokinetic profile of almotriptan (ALM), a serotonin (5-HT) receptor agonist used to treat migraine, when coadministered with timolol (TIM) or verapamil (VER) which are considered as an adjuvant therapy in migraine prevention. This newly proposed method offers a faster alternative to existing chromatographic methods for extraction and determination of ALM in binary mixtures with TIM or VER in rabbit plasma and provides a platform for studying pharmacokinetic parameters. The coadministration of either TIM or VER with ALM resulted in a notable rise in C (maximum plasma concentration) and AUC (area under the plasma concentration-time curve) of ALM, implying possible alterations in the absorption and overall exposure of ALM."

Combination therapy • Journal • PK/PD data • Preclinical • CNS Disorders • Migraine • Ophthalmology • Pain

Prior migraine treatments among patients initiating rimegepant for acute migraine treatment in the United States (AHS 2023) - "Prior migraine treatments evaluated during the 60-month pre-index period included recommended acute and preventative treatments for migraine, including: anticonvulsants (topiramate, divalproex sodium, valproic acid), antidepressants (amitriptyline, duloxetine, venlafaxine, nortriptyline, imipramine), beta-blockers (propranolol, metoprolol, atenolol, nadolol, bisoprolol, timolol), botulinum toxin A, CGRP antagonist monoclonal antibodies (galcanezumab, erenumab, fremanezumab, eptinezumab), other CGRP antagonists (ubrogepant, atogepant), and triptans (sumatriptan, rizatriptan, eletriptan, naratriptan, zolmitriptan, frovatriptan, almotriptan). Patients initiating rimegepant for acute treatment had significant prior experience with other migraine-specific treatments, although the time period may not fully capture migraine treatment history. Most patients had tried at least one prevention agent, with more than half having tried two or more in the prior 5 years. Similarly,..."

Clinical • CNS Disorders • Migraine • Pain

Primary Care Provider Approach to Triptan Selection and Optimal Use of Triptans (AHS 2023) - "The second generation triptans (e.g., almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan) were designed to have improved oral bioavailability, increased duration of half-life, and/or faster onset of action compared with the first-generation medication, sumatriptan. Our study suggests that sumatriptan remains the first choice triptan in primary care with more than 50% of providers using it, followed closely by rizatriptan in about 40% of providers. Most providers are not familiar with almotriptan, frovatriptan, and naratriptan, despite their improved pharmacokinetic profiles. Primary care providers were not aware that naratriptan and frovatriptan are longer-acting agents which may be helpful as bridge therapy and for menstrual migraine."

Clinical • CNS Disorders • Migraine • Pain

Real World Evidence for the Effect of the Introduction of the Gepants and Lasmiditan on the Prescribing of Triptans for the Acute Treatment of Migraine at a Tertiary Headache Center (AHS 2023) - "The introduction of gepants and lasmiditan was not associated with an overall change in triptan prescribing patterns among providers at a tertiary headache center, but was linked to a decrease in naratriptan prescriptions...The introduction of lasmiditan, ubrogepant, and rimegepant in the winter of 2019-2020 presented the first potential alternatives to the triptans...Rizatriptan, sumatriptan, zolmitriptan, frovatriptan, eletriptan, and almotriptan showed no statistically significant change in prescriptions (Figure 1). The gepants and lasmiditan provide additional tools for providers and their patients but have not taken the place of triptans. Future studies should examine the continued evolution of the prescription of acute treatments for migraine."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Drugs for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review. (PubMed, Indian Pediatr) - "We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (oral administration) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans."

Journal • Review • CNS Disorders • Infectious Disease • Migraine • Pain • Pediatrics • Xerostomia

In Vivo Evaluation of Almotriptan malate Formulation through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment. (PubMed, AAPS PharmSciTech) - "For this, the LC-MS/MS bioanalytical method was developed and used for the determination of plasma almotriptan malate concentrations. Results of a pharmacokinetic study revealed that intranasal administration of optimized almotriptan malate formulation enabled an almost five-fold reduction in T and about seven-fold increase in bioavailability in comparison to the currently available oral tablet formulation, suggesting the potential of developed almotriptan malate intranasal formulation in producing a rapid onset of action as well as enhanced bioavailability."

Journal • PK/PD data • Preclinical • CNS Disorders • Migraine • Pain